Laxmi Dental FY26 Revenue Rises 16%; IPO Fund Usage Shift Proposed

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorVihaan Mehta|Published at:
Laxmi Dental FY26 Revenue Rises 16%; IPO Fund Usage Shift Proposed

Laxmi Dental reported a 16.21% revenue growth for FY26 to INR 2,778.58 million, though profit dipped to INR 289.17 million. The board has scheduled the 22nd AGM for September 25, 2026, where shareholders will vote on a special resolution to reallocate unutilized IPO funds toward a new manufacturing plant.

Laxmi Dental FY26 Results: Revenue Up, Profit Under Pressure

Revenue for FY26 reached INR 2,778.58 million, compared to INR 2,391.07 million in the previous year.
Profit After Tax stood at INR 289.17 million for the fiscal year ending March 31, 2026.

Reader Takeaway: Strong digital scanner demand drives 16% revenue growth, while one-time regulatory costs weigh on FY26 profitability.

What just happened

Laxmi Dental Limited released its Annual Report for FY 2025-26, highlighting a 16.21% jump in operational revenue. The company, which operates across 320 cities in India and exports to over 95 countries, is preparing for its 22nd Annual General Meeting on September 25, 2026. A key agenda item is the proposed shift in unutilized IPO proceeds, totaling INR 481.03 million, which management intends to redirect toward land acquisition and a new manufacturing plant for dental labs and aligners.

Why this matters

While topline growth remains robust, the bottom line felt the impact of external and regulatory headwinds. Profit after tax declined from INR 318.34 million to INR 289.17 million. Management attributed this to higher US tariffs, rising non-cash ESOP expenses, and a mandatory one-time gratuity liability of INR 57.79 million linked to new Labour Codes. The previous year’s profit had also received an inorganic boost from a property sale, adding to the year-on-year variance.

Business and Operational Performance

The company is betting heavily on digital transformation. Its scanner business grew 85.91%, while the international laboratory segment saw a 29.15% expansion. Domestic digital penetration in its labs reached 75%, with a strategic goal to push this beyond 90% in the medium term.

Risks to watch

The proposed change in IPO fund utilization is subject to shareholder approval. The plan to acquire land and build a new facility also carries execution risks regarding regulatory clearances. Additionally, investors should note that the company has not recommended a dividend for FY26, as the board seeks to conserve cash for this capital expenditure.

What to track next

Shareholders should closely follow the special resolution at the September 25 AGM. Success here will signal the company’s definitive pivot toward integrating its manufacturing infrastructure, which management believes is essential for long-term scalability despite short-term margin pressures.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.